JIN YI KIM: Open Payments
NPI 1659801132 · BRONX, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,370 in 58 payments from 17 companies in 2025. Trend: 2023 $422 · 2024 $795 · 2025 $1,370
Food & beverage: $1,271Education: $99
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 10 | $287 |
| Astellas Pharma US Inc | 5 | $223 |
| GlaxoSmithKline, LLC. | 10 | $185 |
| AstraZeneca Pharmaceuticals LP | 6 | $132 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $106 |
| Lundbeck LLC | 5 | $90 |
| Amgen Inc. | 4 | $83 |
| Lilly USA, LLC | 2 | $59 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $39 |
Products named: TRELEGY ELLIPTA, AUSTEDO XR, Veozah, UZEDY, XIFAXAN, REXULTI, BREZTRI, OTEZLA.
Industry payments across NY — which companies pay providers there.
